High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?  by Pulsipher, Michael A. et al.
From the 1
logy/B
Schoo
Hema
Vienn
Child
Financial d
Correspon
Divisi
Unive
Medic
.pulsip
 2011 Am
1083-8791
doi:10.101High-Risk Pediatric Acute Lymphoblastic Leukemia:
To Transplant or Not to Transplant?
Michael A. Pulsipher,1 Christina Peters,2 Ching-Hon Pui3Because survival with both chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT)
approaches to high-risk pediatric acute lymphoblastic leukemia (ALL) generally improves through the years,
regular comparisons of outcomes with either approach for a given indication are needed to decide when
HSCT is indicated. Improvements in risk classification are allowing clinicians to identify patients at high
risk for relapse early in their course of therapy. Whether patients defined as high risk by new methods
will benefit from HSCTrequires careful testing. Standardization and improvement of transplant approaches
has led to equivalent survival outcomes with matched sibling and well-matched unrelated donors; however,
survival using mismatched and haploidentical donors is generally worse. Trials comparing chemotherapy and
HSCT must obtain sufficient data about therapy and stratify the analysis to assess the outcomes of best-
chemotherapy with best-HSCT approaches.
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Although the large majority of children with acute
lymphoblastic leukemia (ALL) are cured with chemo-
therapy approaches [1-3], hematopoietic stem cell
transplantation (HSCT) has been used successfully to
treat a portion of very high-risk patients in first remission
(CR1) or at various stages of relapse [4,5]. Through the
years, significant improvements have occurred in both
chemotherapy and HSCT approaches [6]. In addition,
sophisticated methods of risk classification based upon
clinical and molecular characteristics have allowed the
development of approaches targeting intense agents
and/or offering HSCT to the highest risk patients [7-9].
Because both treatment approaches and diagnostic
tools are changing rapidly, clinicians must carefully
follow the field to knowwhenHSCTor chemotherapy
approaches offer the best chance of cure for theirPrimary Children’sMedical Center, Division of Hemato-
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6/j.bbmt.2010.10.005patients. In addition, both treating physicians and
clinical researchers need to understand essential study
design methods necessary for valid comparison of
HSCT and chemotherapy outcomes in order to avoid
bias or inappropriate conclusions [10].
Our review of this topic will begin with a discussion
of current indications for CR1 HSCT from the per-
spective of a chemotherapist, Dr. Ching-Hon Pui,
who leads the St. Jude Total Therapy studies in
ALL. Although other international study groups vary
somewhat in identifying those who should receive
HSCT, the general principles outlined by Dr. Pui
are useful in considering this question. Dr. Christina
Peters, who leads HSCT efforts in Berlin-Frankfurt-
M€unster (BFM)-based studies, will then review key
principles of transplantation learned as the BFM group
carefully standardizedHSCT approaches over the past
decade. Finally, Dr. Michael Pulsipher, a leader
in Children’s Oncology Group (COG) ALL HSCT
efforts, will discuss data and study design elements
that are important in determining which subsets of
children with ALL benefit from HSCT approaches.INDICATIONS FOR TRANSPLANTATION IN
FIRST REMISSION OF CHILDHOODALL:
PERSPECTIVES FROM A CHEMOTHERAPIST
Ching-Hon Pui, MD
Allogeneic HSCT is considered a treatment
modality for patients with ALL who are predicted to
respond poorly to intensive chemotherapy. Therefore,S137
S138 Biol Blood Marrow Transplant 17:S137-S148, 2011M. A. Pulsipher et al.the indications for transplant must be periodically re-
assessed, owing to the continuous improvement in
chemotherapy results, transplantation procedures,
and methods to assess relapse hazard. Small numbers
of eligible patients, strong preference for chemother-
apy or transplant on the part of the physicians, and
a lack of suitable donor are some of the factors that
have prevented stratified randomized trials to directly
compare the efficacy of transplantation to that of
chemotherapy alone in pediatric ALL. Thus, treat-
ment allocation is primarily based on the availability
of a suitable donor.
In a study by the BFM group in patients with high-
risk T cell ALL, the 36 patients who received alloge-
neic transplantation had higher disease-free survival
(DFS) (P 5 .01; 67% 6 8% [SE] versus 42% 6 5%
at 5 years) and overall survival (OS) (P 5 .01; 67% 6
8% versus 47%6 5% at 5 years) than the 120 patients
treated with chemotherapy alone [11]. In a European
multi-institutional study of very high-risk childhood
ALL, the 77 transplanted patients also had a superior
DFS (P 5 .02) than the 280 patients treated with che-
motherapy: 56.7%6 5.7% (SE) versus 40.6%6 3.1%
at 5 years [12]. In this study, however, the difference in
OS rate between the 2 groups was not statistically sig-
nificant, and there were too few patients to perform
meaningful subgroup analyses to identify the specific
subtype(s) that benefited from transplantation (the
‘‘high-risk’’ group was defined by many differing fac-
tors) [12]. Based on the outcome of patients treated
with chemotherapy alone in these 2 studies, one could
argue that approximately one-third of the patients
might have been overtreated with transplantation.
Currently, no genetic abnormality per se is an abso-
lute indication for transplantation because even within
specific genetic subtypes of ALL, there is considerable
heterogeneity in terms of drug resistance because of
a combination of variables, including secondary cooper-
ating mutations, target cells undergoing malignant
transformation, and host pharmacodyamics and phar-
macogenetics [13]. As shown in Table 1, there is no
consensus on the indications for transplantation in
childhood ALL in CR1 among major study groups.Table 1. Indications for Allogeneic HSCT in Children with ALL du
Groups
Study Group
AIEOP/BFM* Induction failure ($5% blasts in marrow) o
(BCR-ABL1) plus positive MRD on day 33
MRD $1023 on day 78 or if MRD data n
Children’s Oncology Group† Induction failure ($25% blasts in marrow)
(matched-related donor; matched-unrela
SJCRH Induction failure ($5% blasts by MRD in ma
induction; MRD $1023 14 weeks after t
AIEOP indicates Associazione Italiana Ematologia Oncologia Pediatrica; BFM, B
Children’s Research Hospital; ALL, acute lymphoblastic leukemia; HSCT, hem
*M. Schrappe and V. Conter (personal communication).
†S. Hunger (personal communication).Discussed here is the perspective of a chemotherapist
on this topic.Philadelphia Chromosome-Positive ALL
A St. Jude study first recognized that childhood
ALL with the t(9;22) (BCR-ABL1) is a heterogeneous
disease and that a substantial proportion of patients,
that is, those with low leukocyte count, could be cured
with chemotherapy alone [14]. This result was con-
firmed by Arico and associates [15] in a large coopera-
tive group study of 326 pediatric patients treated
between 1986 and 1996. Of note, matched-related
transplantation was superior to the other types of
transplantation and to intensive chemotherapy alone
in prolonging DFS and OS in this study [15]. A subse-
quent study of 610 patients treated without ABL inhib-
itors between 1995 and 2006 showed that the overall
outcome had improved with advances in chemother-
apy and transplantation, that transplantation with
matched-related and matched-unrelated transplanta-
tion yielded similar results, and that transplantation
improved DFS but not OS [16]. Early treatment
response assessed by morphologic examination of
blood or bone marrow was the most powerful prog-
nostic indicator in this study. Overall, only 45% of
patients were alive 7 years after diagnosis; the study
did not identify subsets of patients that benefited the
most from transplantation [16].
In a recent Children’s Oncology Group study,
intensive chemotherapy plus continuous imatinib
treatment after conventional remission induction ther-
apy yielded a 3-year event-free survival (EFS) rate of
80%, which was more than twice that of the historic
controls and comparable to those of matched-related
or matched-unrelated transplant [17]. However, the
follow-up duration of this study is too short to deter-
mine whether the treatment with intensive chemother-
apy and imatinib truly improved cure rates and not
merely prolonged DFS. At the time of the report,
positive minimal residual disease (MRD) after conven-
tional remission induction, the most important prog-
nostic factor for childhood ALL, was not significantlyring First Remission Currently Being Assessed in 3 ALL Study
Indications
n day 33 of induction; hypodiploidy <44 chromosomes, t(4;11) or t(9;22)
of induction or on day 78; T cell ALL with prednisone-poor response if
ot available; MRD $1023 on day 78 of induction
on day 29 of induction; hypodiploidy <44 chromosomes; t(9;22) (BCR-ABL1)
ted donor only if day 29 MRD >1% or week 12 MRD >0.01%)
rrow) on day 42 of induction; T cell precursor ALL; MRD$1022 on day 42 of
he start of remission induction; reemergence of leukemia blasts at any level
erlin-Frankfurt-M€unster; MRD, minimal residual disease; SJCRH, St. Jude
atopoietic stem cell transplantation.
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rence of relapse after cessation of therapy in several
cases with positive MRD suggested that this factor
could become important with additional follow-up.
With this uncertainty, it is not surprising that there
is no consensus on the indication of transplantation
for this group of patients (Table 1). The recent advent
of more potent ABL inhibitors and their inclusion into
remission induction treatment might make consensus
even less likely.
Infant ALL with MLL Rearrangements
The prognosis ofMLL-rearranged ALL, including
the t(4;11) with MLL-AF4 fusion, is affected by the
age of presentation, with infant age predicting the
most dismal outcome [18]. Although some small studies
suggested that transplantation improved outcome of
infant cases withMLL rearrangement, results of 3 large
cohort studies failed to show an advantage of transplan-
tation over chemotherapy alone in terms of DFS or sur-
vival after adjustment forwaiting time to transplantation
[18-20]. In fact, patients who underwent mismatched
transplantation had a significantly worse outcome than
those treated with chemotherapy alone in 1 earlier
study [18]. By contrast, 1 of the studies (Interfant-99)
with a longer follow-up, showed that a very high-risk
subgroup of infants with MLL rearrangement (defined
by age\6months and either poor response to glucocor-
ticoid treatment or initial leukocyte count$300 109/
L) benefited from transplantation,with a 64%reduction
in the risk of relapse or death in remission [21]. How-
ever, the finding of this subset analysis needs to be
confirmed, and studies should also be performed on
other subsets characterized by a dismal outcome, such
as MLL-rearranged infant cases with persistent MRD
after remission induction and consolidation treatment
[22]. The indications for transplantation should also be
evaluated in the contextof emergingmolecular therapies
such as FLT3 inhibitors and DNA methyltransferase
inhibitors [23].
High-Risk T Cell ALL
In the BFM 90 and 95 trials, transplantation im-
proved outcome in patients with T cell ALL and
high-risk features, that is, poor response to 7 days of
prednisone and 1 dose of intrathecal methotrexate or
failure to achieve remission ($5% blast in marrow
on day 33 of remission induction) [11]. However,
considering that chemotherapy alone yielded a DFS
approaching 50% in this group of patients treated in
the BFM 95 trial, one could argue that transplantation
was an overtreatment for them. Early T cell precursor
ALL is a recently identified subset of T cell ALL with
immature genetic and immunophenotypic features
and a dismal prognosis (EFS of 22%), despite the
fact that half of the patients received transplantationbecause of high MRD levels after remission induction
[24].Whether transplantation has a therapeutic role in
this group of patients remains to be determined by
studying a larger number of patients.
Hypodiploid ALL
ALL with hypodiploidy\45 chromosomes occurs
in only 1% of childhood ALL. In a recent international
collaborative group study (the largest to date), the 80
patients with chromosomal number \44 in their
leukemic cells fared significantly worse than the 80 pa-
tients with 44 chromosomes in terms of EFS (P5 .01;
30.1% versus 52.2% at 8 years) and survival (P5 .017;
37.5% versus 69% at 8 years) [25]. Transplantation
was performed in first remission in only 9 patients, 5
of whom subsequently had an adverse event. There
was no difference in DFS or OS between patients
who did or did not undergo transplantation [25].
However, the efficacy of transplantation could not be
adequately addressed in this study because only
a very small number of patients were transplanted.
and the MRD status after remission induction was
unknown in these patients.
Poor Early Responders
Early response to treatment is perhaps the most
important prognostic factor because it accounts for
the drug sensitivity of leukemic cells, the host pharma-
codynamics and pharmacogenetics, the treatment ad-
ministered, and the patient compliance [26]. Among
various methods to assess treatment response, MRD
determination in bone marrow samples collected
during or at the end of induction is the most reliable.
Remission induction failure is oneof theworst prognos-
tic factors in ALL, withDFS ranging from21% to 36%
in recent studies [12,27-29]. It has been universally
regarded as an indication for transplantation although
there is no uniform definition for ‘‘induction failure,’’
which is generally based on the finding of M2 to M3
marrow between day 29 and day 42 of remission
induction. In the study of Oudot et al. [29], patients
with Philadelphia chromosome-positive ALL or those
with T cell ALL and no mediastinal mass had a high
risk, patients with T cell ALL and a mediastinal mass
had an intermediate risk, and the other B cell precursor
cases had a low risk of induction failure. Whether
these patients have different salvage rates remained to
be determined. Matched-related transplantation and
chemotherapy yielded a similar outcome in this study
[29].However, in the study of Balduzzi et al. [12], trans-
plantation prolonged DFS. Recent MRD studies
showed that patients with 1% or more leukemic cells
at the end of 4 to 6 weeks of remission induction have
a prognosis that is almost as poor as that of patients
who fail to achieve clinical remission by traditional
morphologic standard [26,29], an observation that
S140 Biol Blood Marrow Transplant 17:S137-S148, 2011M. A. Pulsipher et al.challenged the currentdefinitionof induction failure. In
the recently completed St. Jude Total Therapy Study
XV, transplantation was performed in 9 patients with
1% or more leukemic cells in bone marrow at day 46
of remission induction, and yielded a 5-year EFS of
55.6% 6 26.2% and 5-year survival of 87.5% 6
13.8% [1]. Additional studies are needed to determine
whether transplantation improves outcome in this set-
ting.
Conclusion
There is no absolute indication for transplantation
in children with ALL who are in first remission. In
view of the dismal outcome of poor early responders
with Philadelphia chromosome-positive ALL, early
T cell precursor ALL, or infant ALL with MLL rear-
rangement, these patients are reasonable candidates
for the evaluation of transplantation in first remission.HSCTOUTCOMES OF BFM TRIALS: RECENT
RESULTS, CHALLENGES MOVING FORWARD
Christina Peters, MD
The majority of children and adolescents with
ALL can be cured with multimodal chemotherapy
[30]. However, patients with the very high-risk ALL
(HR-ALL) or patients who have relapsed have a signif-
icantly worse prognosis compared to other patients
with ALL [31-34]. These patients require additional
therapapeutic approaches after achieving remission.
Allogeneic HSCT can effectively induce immuno-
logical antileukemic control in patients with ALL
by means of the graft-versus-leukemia (GVL) effect,
but treatment-related mortality (TRM) remains a seri-
ous problem [35,36]. In addition, the heterogeneity
of available data regarding patient selection,
transplantation procedures, and study endpointsTable 2. Indications for Allogeneic Stem Cell Transplantation in A
MRD-SR M
HR criteria (in hierarchical order) No CR d33 MMD
PPR + (9;22) MMD
PPR + (4;11) MD
PGR + (9;22) no
PGR + (4;11) MSD
PPR + * no
‘‘Favorable’’ PPR† no
MSD indicates matched sibling donor; MD, matched donor (well-matched, unre
indicated; ALL, acute lymphoblastic leukemia; MRD, minimal residual disease.
MRD-SR: MRD negativity after 4 and 12 weeks induction treatment, measure
MRD-MR: any MRD positivity after 4 and 12 weeks induction treatment, but
MRD-HR: MRD $1023 at week 12 (TP2).
*PPR + pro-B ALL or T-ALL and/or M3 d15 and/or white blood cell count (W
†PPR + none of the above criteria.hampers the interpretation of the value of HSCT
[37]. To overcome this challenge, in 2003, the
Berlin-Frankfurt-M€unster (BFM)-Study group initi-
ated a prospective international multicenter trial
(ALL-SCT-BFM 2003) for allogeneic HSCT in chil-
dren with ALL in first, second, or subsequent remis-
sion who had an indication for HSCT according to
the frontline/relapse chemotherapy protocols [38].
In addition to developing a standardized approach
to HSCT in childhood ALL, the primary objective of
this trial was to evaluate whether HSCT from an
HLA-identical matched sibling donor (MSD) is equiv-
alent to HSCT from a very well-matched unrelated
donor (MD). Secondary objectives were to compare
the efficacy between HSCT from HLA-mismatched
donors (MMD) and HSCT from MD/MSD, and to
determine the incidence of acute and chronic graft-
versus-hose disease (aGVHD, cGVHD) after HSCT.
In 2007, the trial was extended to additional transplant
units internationally. This extension of the study has
been called the ALL-SCT-BFM-international trial
(ALL-SCT-BFMi).
Current Prognostic Factors and Indications for
Allogeneic HSCT
As reviewed by Dr. Pui, there are several risk fac-
tors for a poor prognosis in childhood ALL that are
discernable at diagnosis (cytogenetic characteristics,
time and site of relapse, etc.). Additionally, response
to induction treatment measured by morphology
and/or detection of MRD has a strong predictive value
and defines SCT indications [22,34,39,40]. Further
details are shown in Table 2 for ALL (CR1) and
Table 3 for ALL (.CR1).
Donor Selection and Stem Cell Source
MSD HSCT has generally led to the best survival
rates and is considered the gold standard for allLL in CR1 According to the BFM Criteria
PCR-MRD Results
RD-MR
MRD-HR
No MRD
ResultMRD-TP2 $1023 MRD-TP2 $1022
MMD MMD MMD MMD
MMD MMD MMD MMD
MD MD MMD MD
MD MD MMD MD
MSD MD MMD MSD
no MD MMD MD
no MD MMD no
lated); MMD, mismatched donor; no, no stem cell transplantation (SCT)
d with 2 independent targets with a sensitivity of #1024.
<1023 at week 12 (TP2).
BC) >100,000/mL.
Table 3. ALL-SCT-BFM 2003/BFMi Indications for Allogeneic
Stem Cell Transplantation in ALL after First Relapse
High risk (S3/S4):
— T-lineage: any BM involvement
— BCP-ALL: very early BM involving relapse, early
isolated BM relapse
— >CR 2: according to risk for TRM
MMD
Intermediate risk (S2, MRD* $1023):
— BCP-ALL: early combined BM relapse, late BM
involving relapse
MD
Intermediate risk (S2, MRD* <1023):
— BCP-ALL: early combined BM relapse, late BM
involving relapse
MSD
MSD indicates matched sibling donor; MD, matched donor (well-
matched, unrelated); MMD, mismatched donor; MRD, minimal residual
disease.
Timepoint of relapse:
Very early: <18 months after primary diagnosis.
Early: $18 months after primary diagnosis and <6 months after
cessation of front-line therapy.
Late: $6 months after cessation of front-line therapy.
*MRD detected after the second induction block; if no MRD is available:
MSD-SCT is indicated, MD-SCT indication is dependent on conven-
tional clinical risk factors.
Table 4. ALL-SCT-BFM 2003/BFMi Definition of Donor
Groups by HLA-Matching and Relationship
Identity of
HLA Alleles*
Sibling
Donor
Family
Donor
Unrelated
Donor†
10/10 MSD MD MD
9/10 MD MD
<9/10 MMD MMD
MSD indicates matched sibling donor; MD, matched donor; MMD,
mismatched donor; ALL, acute lymphoblastic leukemia; SCT, stem cell
transplantation.
*High-resolution typing of HLA-A, HLA-B, HLA-C, HLA-DRB1, and
HLA-DQB1.
†If no suitable donor is available cord blood (CB) from a 6/6 matched
unrelated donor is an accepted alternative for MD-Indications, and
<6/6 matched unrelated CB for MMD-Indications (only valid in trial
ALL-SCT-BFMi).
Biol Blood Marrow Transplant 17:S137-S148, 2011 S141High-Risk Pediatric ALLindications [41]. Because only 20% to 25% of children
with an indication for allogeneic HSCT have anMSD,
the availability of volunteer HLA matched unrelated
donors (MUD) has widened the donor pool over the
past decade [42]. The chance of finding a suitable do-
nor mainly depends on ethnic group (ranging from
60%–70% for Caucasians to\10% for patients be-
longing to some ethnic minorities) and the frequency
of theHLA phenotype of the patient [43]. The primary
aim of our trial was to evaluate if a well-matched unre-
lated donor (MD) is equivalent to an MSD. To assess
this accurately, high-resolution (allele level) HLA-
typing including the HLA-C locus was required, and
an algorithm was developed to choose the best donor
if more than 1 was available. The algorithm was as
follows: mismatch at the allele level was considered
superior to an antigenmismatch, the subsequent prior-
ities were the matching of the cytomegalovirus (CMV)
serostatus (CMV antigen-positive donor for a positive
recipient), then gender (male donor for male recipient)
and age (younger donor for children) of donor and re-
cipient. Details for donor definitions are shown in
Table 4.
Preferably, unmanipulated BM was chosen as the
stem cell source from MD in ALL-SCT-BFM 2003,
as it was shown that the use of peripheral blood stem
cells (PBSCs) is associated with a higher TRM and
a higher incidence of cGVHD [44-46]. T cell
depletion was performed only in a MMD situation.
Conditioning Regimen
The choice of the conditioning regimen has a signif-
icant impact on survival after HSCT. It was shown
retrospectively that conditioningwith total-body irradi-
ation (TBI)/etoposide (TBI/VP16) was comparable
with TBI/ARA-C/melphalan (MEL) and superiorto TBI/cyclophosphamide (Cy). Busulfan/CY/MEL
(BU/CY/MEL) as an irradiation-free conditioning
was inferior because of higher incidence of relapses as
well as TRM [47-49]. Therefore, the current standard
backbone for MSD/MD consists of fractionated TBI
(12 Gy) and VP16. Patients who are ineligible for TBI
because of young age or previous therapy can
substitute TBI with i.v. BU. For MMD, additional
TBI or BU, fludarabine (FLU), and CY were given.
Alternatively, FLU/thiotepa (THIO)/MEL was an
acceptable combination for MMD transplant for
patients at high risk for TRM. In patients with t(4;11),
the benefit of allogeneic HSCT could not be clearly
demonstrated by retrospective analysis [18]. As out-
come after treatment by chemotherapy only is also
not satisfying, it was decided to choose a conditioning
regimen consisting of BU, CY, and MEL for these
patients, as this regimen was shown to be effective in
patients with juvenile myelomonocytic leukemia and
acute myelogenous leukemia (AML) [50].GVHD Prophylaxis and Therapy
Heterogeneities in GVHD prophylaxis and
therapy are a structural weakness of retrospectively
analysed patient cohorts [51,52]. Therefore, it was
a major goal of our trial to apply a well-standardized
and risk-adapted GVHD prophylaxis approach. In
MSD, GVHD prophylaxis consisted of cyclosporine
(CSA) only; in MD, additional short methotrexate
(MTX) and antithymocyte globulin-fresenius (ATG-
F) were administered. In MMD, CD34-positive selec-
tion or CD3/CD19 depletion were performed, and no
pharmacologic immunosuppression was given [53,54].Outcomes
Between September 2003 and September 2009, 624
patients were recruited; 387 patients (188 in CR1, 199
$CR2) were transplanted in 27 participating centers
in Austria, Germany, and Switzerland. Mean age of
the patients at HSCT was 10 years (range: 0.5-18);
97 patients received a MSD-HSCT, 251 patients
S142 Biol Blood Marrow Transplant 17:S137-S148, 2011M. A. Pulsipher et al.aMD-HSCT, and 39 patients aMMD-HSCT.Median
follow-up was 2.4 years. Unmanipulated bone marrow
was used in 81% of MSD-HSCT and in 65% of
MD-HSCT as determined by the protocol.
Acute GVHD (grade III and IV) occurred in 10%
of all patients, the 2-year cumulative incidence of ex-
tensive cGVHD was 15% after MSD and 12% after
MDHSCT. The 4-year probability of EFS (pEFS) af-
ter MSD-HSCT was equivalent to MD-HSCT (70%
versus 68%; P5 .37) (Figures 1 and 2). The cumulative
incidence of TRM after 1 year was 5% for MSD and
8% for MDHSCT (n.s.). The 2-year cumulative inci-
dence of relapse was 18% after MSD-HSCT and 20%
after MD-HSCT (n.s.). For patients with very high
risk of relapses, the results for MD/MSD HSCT (n
5 187) and MMD HSCT (n 5 39) differed signifi-
cantly (2-year pEFS 68% versus 28%; P \ .001).
The 2-year incidence of relapse was 23% after MSD/
MD HSCT and 37% after MMD-HSCT (n.s.). The
1-year incidence of TRM was 8% after MSD/MD-
HSCT and 22% after MMD-SCT (P 5 .04). Overall,
MMDHSCT showed a significantly worse result with
higher TRM and higher relapse rates. For patients
beyond CR1 (n 5 25) transplanted from a MMD,
the 2-year pEFS was only 19%.
The results from this ALL-SCT-BFM 2003 trial,
which is the largest prospective, international, and mul-
ticenter HSCT trial ever performed in childhood ALL,
demonstrate the feasibility of a harmonized HSCT
approach acrossmultiple international centers.Wedem-
onstrate that allogeneicHSCT fromwellHLA-matched
unrelated donors or geno-identical sibling donors are
effective treatment options with acceptable toxicity in
children with high-risk ALL. Precise HLA typing and
matching and the inclusion of ATG resulted in a low in-
cidence of extensive cGVHD, an important achievement
for the quality of life in children and adolescents.Figure 1. Probability of EFS according toConclusion
The definition of indications for allogeneic HSCT
in children with HR-ALL in the first remission or after
the first or subsequent relapse depends on biologic fea-
tures, response to treatment, and survival after chemo-
therapy alone. HSCT indications have to be defined
prospectively and must be reevaluated and reconfirmed
at intervals dependent on modifications and improve-
ments of the chemotherapeutical approaches of the
frontline and relapse protocols. Furthermore, a close co-
operation between chemotherapy study groups and
HSCT societies enables identification of patients at
the highest risk of relapse after HSCT.
There is a strong need for prospective HSCT tri-
als, ensuring a well-standardized procedure regarding
all relevant components that are potentially responsi-
ble for TRM and late effects. Subsequent BFM
ALL-HSCT trials will focus on controlled modifica-
tions and interventions in patients at highest risk for
relapse after HSCT. The most burning questions are:
 How to reduce leukemic burden before HSCT?
 Whether TBI can be substituted without increasing
relapse risk?
 Who is the best HLA-mismatched donor: haplo-
identical family members, unrelated bone marrow,
or unrelated cord(s)?
ANALYSIS OF COMPARATIVE HSCT/
CHEMOTHERAPY STUDIES: THE PROCESS
OF DEFINING WHEN HSCT SHOULD BE
CONSIDERED IN PEDIATRIC ALL
Michael A. Pulsipher, MD
Defining when HSCT is appropriate therapy for
the ever-multiplying redefinitions of clinical,molecular,
and MRD-based risk classifications for children withtransplant indication and donor type.
Figure 2. Probability of survival according to transplant indication and donor type.
Biol Blood Marrow Transplant 17:S137-S148, 2011 S143High-Risk Pediatric ALLALL is a daunting task. In the past decade significant
improvements in HSCT have led to less TRM and bet-
ter survival after unrelated donor transplantation [6],
less GVHD in pediatric recipients [55], decreases in
TRM, and better survival in unrelated cord blood trans-
plantation [56], a possibility of decreased relapse using
KIR mismatching or double cord blood approaches
[57,58], and the beginning a series of both targeted
and nontargeted cellular therapeutic therapies [4,59].
As these advances occur, equally compelling advances
occur in chemotherapy approaches with the
introduction of novel and targeted agents, better
definition of high-risk groups, and intensification of
therapy in order to prevent relapse [23]. The pace of
advancement in both fields makes it imperative that
chemotherapists and HSCT practitioners work to-
gether to continually redefine when HSCT should be
used for children with ALL.Approaches to Considering HSCT for High-Risk
Pediatric ALL
A major challenge in deciding the comparative
efficacy of HSCT for pediatric ALL patients is that
the modality is not conducive to randomized trials,
and past attempts at randomization failed as improve-
ments in HSCT techniques led to widespread non-
compliance [60]. As highlighted by Dr. Peters above,
modern allogeneic transplantation is an effective,
well-established curative therapy for ALL that com-
bines intensive therapy and an immunologic effect
(GVL) that can overcome chemotherapy resistance.
Our key question is not whether it works, but whencan it offer an advantage compared to available
therapies.
Figure 3 illustrates an approach that could be con-
sidered when patients display clinical characteristics
that render them to have an unacceptable relapse
hazard with established approaches. The first task is
to define unacceptable risk that should be considered
for each risk group in comparison to a non-HSCT al-
ternative. For example, in CR1 patients, many studies
show survival after HSCT with well-matched donors
in the 60% to 70% range [61,62]. If a patient has
a risk factor resulting mostly in early relapse, the
likelihood of achieving a second remission is just
under 70% [63]. Many of these patients may not be
able to get to HSCT because of significant organ
toxicity, infections, or insurance issues. Of those who
undergo HSCT for early relapse, survival is in the
30% to 40% range [64]. Adding this up, it is likely
that survival of patients with this group would increase
if an advantage of at least 15% to 20% over chemo-
therapy were achieved with HSCT in CR1. If we
take the low end of HSCT survival in CR1 (60%),
that would mean that a risk factor identifying patients
with\40% survival would be a reasonable candidate
to consider for HSCT if they achieve remission. Other
approaches and logic can be used to decide unaccept-
able risk, but agreement between transplant physicians
and chemotherapists on which approach should be
taken is important to protect the integrity of studies.
It is vital that patients achieve CR before consider-
ing them for comparative study, as both chemotherapy
and HSCT for patients who do not achieve remission
result in dismal outcomes. Once remission is achieved,
Figure 3. Consideration of the use of HSCT for newly defined high-
risk patients.
Table 5. Considerations for Studies Comparing HSCT
with Chemotherapy
1. Comparison should start at the time when patients obtain a remission.
A. Chemotherapy event analysis starts at median time to transplant.
B. Intent to treat analysis can be used based upon donor availability.
2. HSCT and chemotherapy cohorts must be carefully defined.
A. Disease appropriate chemotherapy for era necessary.
B. Patients undergoing HSCT must be analyzed in appropriate
outcome categories (remission, regimen, donor).
3. Risk groups must be defined carefully.
A. Combining high and intermediate groups may dilute an effect
4. Significant treatment advances or risk group changes require careful
analysis.
A. Discovery of a better or worse risk group 5 separate analysis
versus HSCT.
HSCT indicates hematopoietic stem cell transplantation.
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HSCT should be answered. The major consideration
will be whether a promising alternative therapy exists.
Most new chemotherapeutic interventions will not
have preliminary data so compelling that a major
difference in outcome could be anticipated; therefore,
clinicians can decide to either perform HSCT on
all patients who receive the novel intervention or
a high-risk subset. In cases where new approaches are
exceptionally promising, investigators may choose to
perform HSCT only as a rescue strategy after relapse.
Whichever approach is chosen, careful comparison of
outcomes with patients who do not undergo HSCT
should be performed so that the efficacy of HSCT
for that indication versus chemotherapy can be dis-
cerned.
Necessary Elements for Comparative Studies
of HSCTand Chemotherapy
Table 5 identifies several areas that are often over-
looked when attempts at comparison of HSCT with
chemotherapy are performed. It is essential to only
include patients who achieve a clinical state where che-
motherapy or HSCT has a reasonable chance of cure.
Those not attaining remission, therefore, must be ex-
cluded, as a disproportionate number of these patients
in either arm would skew the results. Well-established
statistical methods such as adjusting the chemotherapy
arm for median time to transplant and intent-to-
treat based on a clear marker such as availability ofa predefined type of donor can then be incorporated
if feasible.
Amajor problemwithmany past comparative stud-
ies is failure to recognize substantial differences in
outcome when differentHSCTmethods are employed
and different chemotherapy regimens are pursued.The
following characteristics have been shown to result in
major differences in survival after HSCT for high risk
ALL: (1) allogeneic versus autologous donor, (2)
well-matched related/unrelated donor versus mis-
matched or haploidentical donor, (3) myeloablative
TBI-based regimen versus non–TBI-containing or
reduced-intensity regimen [61], (4) cord blood HSCT
utilizing adequate matching/adequate cell dose versus
inadequate matching/cell dose. Myeloalbative TBI-
based regimens using well-matched allogeneic donors
(or appropriately matched and dosed cord donors)
generally have similar outcomes and can be combined
in analyses, but recipients of autologous, haplo-
identical or significantly mismatched grafts or non-
TBI/reduced-intensity approaches must be analyzed
separately. In a similar fashion, patients on a chemo-
therapy comparative arm should be treated with an
era and disease stage–appropriate chemotherapy regi-
men. Patients receiving inadequate chemotherapy
approaches should be excluded from the comparison
arm or analyzed separately. Sufficient data must be
collected to make these distinctions.
Finally, if high-risk cohorts are not defined cor-
rectly, comparative analysis of HSCT versus chemo-
therapy can be misleading. An example illustrating
this is found in the treatment of MLL1 high-risk in-
fants with CR1 transplantation. In a retrospective
study of children (including infants) with 11q23 abnor-
malities (MLL rearrangement) treated between 1983
and 1995, investigators showed inferior outcome
with HSCT compared to chemotherapy [18]. A recent
report from COG investigators looking at infants with
MLL1 leukemias showed no advantage with CR1
transplant [20]. One could conclude that there is no
role for HSCT in CR1 for high-risk MLL1 infants;
however, both studies suffered from a heterogeneous
Table 6. Possible Indications for HSCT in Pediatric ALL
CR1 risk groups under study:
Primary induction failure
Persistent MRD after consolidation
t(9:22) Philadelphia chromosome positive*
Extreme hypodiploidy (<44 chromosomes)
Infants with MLL rearrangements <6 m with HR characteristics
New high-risk CR1 groups not yet being used for treatment
assignment:
Early T cell precursor ALL
T cell ALL lacking bi-allelic TCR gamma locus deletions
IKZF1 deletions (associated with JAK1&2 deletions and deletion of
CDKN2A/B)
Gene cluster group 8
CR2 risk groups under study:
High risk
 Isolated marrow relapse on treatment or within 6 months of completion
of treatment (or 36 months from diagnosis—COG definition)
 Combined marrow and extramedullary relapse within 18 months
of diagnosis
Intermediate risk
 Isolated extramedullary relapse within 18 months of diagnosis
 Marrow relapse (isolated or combined) more than 6 months after
completion of treatment or 36 months form diagnosis (becomes high
risk with persistent MRD after induction)
CR3+ risk groups under study:
Any second or greater relapse, whether marrow, isolated extramedullary
relapse, or combined
COG indicates Children’s Oncology Group; MRD, minimal residual
disease; HSCT, hematopoietic stem cell transplantation; ALL, acute
lymphoblastic leukemia.
*Early COG data shows promising 3-year survival. If verified, Ph+ CR1
transplantation may later be based upon persistent MRD.
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procedures. The major concern with the analysis of
these studies, however, is that the defined risk groups
contained patients at high, intermediate, and lower
risks of relapse with chemotherapy approaches. At
the time of the first report, older children with 11q23
had higher rates of survival with chemotherapy ap-
proaches (exceeding 60%) compared to the youngest
infants, where survival was very poor. The intensive
chemotherapy used for the recent COG study resulted
in a cure rates for infants greater than 6months that ex-
ceeded 50% [65], whereas those\6 months with high
white blood cells count (WBC) had very low rates of
survival (\20%). Because chemotherapy cured 50%
to 60%1 of a large amount of the cohort, HSCT,
which generally cures about 55% of infants [66], did
not improve outcomes. So what about targeting
HSCT where it works best, to only the high-risk co-
hort? The Interfant group recently used this approach
by dividing patients into 3 risk categories; the highest
risk group was defined by MLL positivity, age \6
months, and either WBC counts$300 K/mL or pred-
nisone poor response. The group then restricted trans-
plantation to the highest risk cohort, although
transplant was not mandated. Survival after HSCT of
medium- and high-risk patients was similar (57%
and 56%), but chemotherapy outcomes were dramati-
cally different, with DFS of 48% of the medium-risk
and 14% of the high-risk children. After appropriate
adjustments for waiting time for HSCT, 4-year OS
was superior for HSCT in the HR cohort (66 6
12% versus 19 6 6%, P 5 .001) [21]. The differing
conclusions of these studies regarding the efficacy of
transplantation in MLL1 infants is a result of stan-
dardization of HSCT approaches and better definition
of risk groups.High-Risk Areas Where HSCTApproaches
Could be Considered
Table 6 lists several risk groups where HSCT is
being assessed and/or practiced by some groups.
Most of the indications listed for relapsed and multiple
relapsed ALL are less controversial, having been veri-
fied by several studies [9,61,67]. The CR1 indications
engender more controversy, although most groups
feel that primary induction failure patients who
eventually achieve a CR should receive HSCT in
CR1 [12,62]. In addition, most groups feel that
patients with persistent MRD define a very high-risk
group where HSCT is a viable option [9]. Ph1 ALL
treatment approaches are undergoing significant
changes as data using tyrosine kinase inhibitors will
dramatically redefinewho should and should not receive
HSCT over the next few years [17]. Although HSCT
results for extreme hypodiploidy have not been re-
ported in large numbers, survival with chemotherapyalone is poor [25], and unpublished CIBMTR data
on 37 pediatric patients with hypodiploid ALL trans-
planted between 1990 and 2005 showed a 2-year OS
rate of 68% (M. Eapen, personal communication),
consistent with outcomes of CR1 transplantation for
children with other risk factors. As reviewed above,
a selected group of very high-risk MLL1 infants
who achieve CR and have favorable donor options
may benefit from HSCT [21].
There are several risk groups listed in Table 6 that
have been recently defined based upon elegant molec-
ular studies [8,24,68-70]. Some of these groups have
data mature enough to consider testing the role of
HSCT, whereas others require further testing in
wider cohorts to verify their predictive power. The
approach outlined in Figure 3 should be considered
as these and other risk factors begin to be used to
define therapeutic approaches in the coming years.
Conclusion
The field of pediatric ALL is rapidly advancing as
new agents are being incorporated into up-front
protocols and molecular diagnostics and sensitive
response measures define risk groups more accurately.
The field of HSCT is also rapidly advancing as
improved approaches decrease TRM and improve
GVL, and targeted cellular therapies currently in early
development may offer new approaches to very high-
risk disease. Careful collaboration between HSCT and
S146 Biol Blood Marrow Transplant 17:S137-S148, 2011M. A. Pulsipher et al.chemotherapy practitioners is needed to develop
rational approaches and analyze outcomes using
appropriate techniques. Such efforts will help optimize
ALLtherapy, targetingHSCTwhere it ismost effective.ACKNOWLEDGMENTS
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